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Abstract
Programmed cell death-ligand 1 (PD-L1) has recently been shown to play a role in the 
regulation of epithelial-to-mesenchymal transition (EMT); however, the relationship 
between PD-L1 expression, EMT and the inflammatory tumour microenvironment has yet 
to be investigated in thyroid cancer. To address this issue, we examined the expression of 
CD8, PD-L1 and the EMT markers E-cadherin and vimentin in a cohort of 74 papillary thyroid 
cancer (PTC) patients and investigated the association of these with clinicopathologic 
characteristics and disease-free survival (DFS). The relationship between PD-L1 and EMT 
was further examined in three thyroid cancer cell lines via Western blot and live cell 
imaging. In order to expand our in vitro findings, the normalised gene expression profiles 
of 516 thyroid cancer patients were retrieved and analysed from The Cancer Genome Atlas 
(TCGA). PD-L1 positivity was significantly higher in PTC patients exhibiting a mesenchymal 
phenotype (P = 0.012). Kaplan–Meier analysis revealed that PD-L1 (P = 0.045), CD8 (P = 0.038) 
and EMT status (P = 0.038) were all significant predictors for DFS. Sub-analysis confirmed 
that the poorest DFS was evident in PD-L1 positive patients with EMT features and 
negative CD8 expression (P < 0.0001). IFN-γ treatment induced upregulation of PD-L1 and 
significantly promoted an EMT phenotype in two thyroid cancer cell lines. Our findings 
suggest that PD-L1 signalling may play a role in stimulating EMT in thyroid cancer. EMT, CD8 
and PD-L1 expression may serve as valuable predictive biomarkers in patients with PTC.
Introduction
The incidence rate of thyroid cancer has risen rapidly 
over the last 4 decades (1). Differentiated thyroid cancers 
(DTCs), derived from thyroid follicular cells, are the most 
common subtype, accounting for over 90% of all newly 
diagnosed cases (2). The mounting incidence rate has 
been attributed to improvements in access to health care 
systems, increased incidental detection on imaging, more 
widespread diagnostic testing of asymptomatic thyroid 
-20-0268
Key Words 
 f thyroid cancer
 f epithelial-to-mesenchymal 
transition








This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-20-0268
https://ec.bioscientifica.com © 2020 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 08/03/2021 12:02:13AM
via James Cook University and James Cook University





nodules, a rise in the volume and extent of surgery, and 
modifications in pathology practices (3). However, recent 
evidence supports a true increase in the occurrence of the 
disease, possibly due to hormonal, environmental, and 
genetic factors (4).
Whilst the majority of patients with DTC have 
a favourable prognosis, 1–9% present with distant 
metastasis at the time of initial diagnosis (5), and 7–23% 
show distant metastasis during follow-up (6). Moreover, 
25–50% of patients with locally advanced or metastatic 
DTC become refractory to radioactive iodine (RAI) 
therapy (7). Inoperable or RAI-refractory metastatic DTC 
is associated with a 10-year survival of only 10%, and 
restricted treatment options are currently available (7).
Following initial surgery, the american joint committee 
on cancer (AJCC)/international union against cancer 
(UICC) tumour node metastasis (TNM) staging system 
is commonly implemented to predict disease-specific 
mortality and is consulted when tailoring decisions 
concerning postoperative adjunctive therapy. Whilst the 
AJCC/UICC TNM staging provides important information 
regarding mortality, it inaccurately predicts the risk of 
persistent or recurrent disease following initial therapy (8). 
Research is needed to establish whether the inclusion of 
additional variables can enhance the predictive capabilities 
of the current AJCC/UICC TNM staging system.
Programmed cell death protein 1 (PD‐1), an 
inhibitory costimulatory molecule expressed on activated 
T, B, and NK cells, plays a critical role in the regulation of 
peripheral tolerance (9). Two PD‐1 binding ligands have 
been identified; programmed death ligand 1 (PD‐L1) and 
programmed death ligand 2 (PD‐L2) (9). PD‐L1 is expressed 
by various human tumours and, following binding to 
PD-1, has been shown to induce potent inhibition of 
T-cell mediated anti-tumoural immunity (10). Elevated 
PD‐L1 levels have been associated with a poor prognosis 
in multiple cancer types (11). We have completed a 
meta-analysis confirming that non-medullary thyroid 
cancer patients expressing PD-L1 were three times more 
likely to have a poorer disease-free survival (DFS) than 
patients who did not have positive PD-L1 expression (12). 
Immunotherapies targeting the PD-1/PD-L1 pathway 
have demonstrated durable responses in selected patients 
across multiple cancer types, including thyroid cancer (13, 
14). However, optimal biomarkers predictive of patient 
response are currently lacking (15).
Epithelial-to-mesenchymal transition (EMT) is a 
biological process which plays a central role in cancer 
progression, metastasis, and drug resistance. During 
EMT, a polarised epithelial cell, which interacts with 
the basement membrane, adopts a mesenchymal cell 
phenotype, which is associated with an enhanced 
migratory capacity and invasiveness, greater resistance 
to apoptosis, and markedly increased production of 
extracellular matrix components (16). Throughout this 
process, epithelial markers including epithelial cell 
adhesion molecule (EpCAM) and E-cadherin are down-
regulated, whilst the mesenchymal markers vimentin and 
N-cadherin increase in expression. Vimentin has gained 
much importance as a canonical marker of EMT, with 
its overexpression associated with accelerated tumour 
growth, invasion, and poor prognosis (17). E-cadherin is a 
member of the cadherin family that is primarily detected 
in epithelial cells. Decreased E-cadherin expression 
reduces cell-cell contact and promotes EMT induction, 
resulting in tumour motility (17). Activation of EMT has 
recently been shown to play a key role in thyroid cancer 
progression, namely by promoting capsular invasion, 
extrathyroidal extension and both local and distant 
metastasis (18). Therefore, E-cadherin and vimentin are 
promising biomarkers associated with invasiveness, poor 
differentiation and malignant phenotype. 
A bidirectional relationship has recently been 
established between EMT and PD-L1 expression (19, 20, 
21, 22). Preliminary observations point to a potential role 
of EMT markers as predictors of patient response to PD-1/
PD-L1 axis therapies (21). Cancers containing a high level 
of pre-existing T cell infiltrate and a pro-inflammatory 
IFN signature, referred to as ‘hot’ tumours, have also been 
shown to more readily respond to PD-1/PD-L1 directed 
immunotherapies blockade (23). However, the relationship 
between T cell infiltrate, PD-L1 and EMT status, and their 
influence on the progression and metastasis of human 
thyroid cancer, has yet to be investigated. To address 
this issue, we examined the expression of CD8, PD-L1 
and the EMT markers E-cadherin and vimentin in a 
cohort of PTC patients and investigated the association 
of these with clinicopathologic characteristics and DFS. 
The relationship between these markers were further 
investigated in three thyroid cancer cell lines via Western 
blot and IncuCyte live cell imaging.
Materials and methods
Patient characteristics
Ethics approval was obtained from the south west 
Sydney Local Health District Human Research Ethics 
Committee via the Centre for Oncology Education and 
Research Translation (CONCERT) Biobank, Australia/
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TCRC/3/02-03-2015 (24). In this study, the archived 
paraffin embedded tissues from 74 PTC patients that 
underwent surgical resection within the south west 
Sydney Local Health District from 2006 to 2015 were 
obtained. Patient demographics and clinicopathologic 
parameters, including age, sex, tumour stage, tumour 
size, capsular invasion, extrathyroidal extension, 
lymphovascular invasion, multicentricity, presence of 
concurrent lymphocytic thyroiditis and lymph node 
metastasis, were acquired via retrospective medical record 
review. Standard American Joint Committee on Cancer, 
8th edition, tumour-node-metastases (TNM) scoring was 
implemented for thyroid cancer staging. All patients were 
followed up for survival status until October 2019. 
DFS was defined as the period between completion 
of primary treatment and detection of residual disease, 
recurrent disease or death. This definition was adopted 
from the 2015 American Thyroid Association (ATA) 
Management Guidelines (25). An excellent response 
(absence of persistent tumour) following initial therapy 
was defined as negative imaging and either a low serum 
thyroglobulin (Tg) during thyroid stimulating hormone 
(TSH) suppression (Tg < 0.2 ng/mL) or following stimulation 
(Tg < 1 ng/mL). A structural incomplete response was 
defined as structural or functional evidence of disease with 
any Tg level, whilst a biochemical incomplete response 
was designated to patients with negative imaging and a 
suppressed Tg ≥ 1 ng/mL or a stimulated Tg ≥ 10 ng/mL. 
Patients that did not experience tumour recurrence were 
censored at the last follow-up contact.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) tissues were 
collected from 74 patients with a confirmed diagnosis 
of PTC and were used to construct tissue microarrays 
(TMAs). Considering spatial heterogeneity, duplicate 
tissue cores of 0.6 mm diameter were obtained from the 
normal tissue, tumour centre and tumour periphery. 
Tissue blocks were cut into 4-μm sections for analysis. 
Sections were stained with anti-PD-L1 (clone SP263) 
rabbit monoclonal primary antibody (Ventana Medical 
Systems) on the Ventana BenchMark Ultra automated 
staining platform using the OptiView Detection Kit. 
The Leica Bond III Immuno-autostainer was used for 
CD8 staining with the mouse anti-human CD8 clone 
C8/144B, 1:100 (DAKO). TMAs were also stained with 
the monoclonal mouse anti-human e-cadherin clone 
NCH-38, 1:100 (DAKO) and monoclonal mouse anti-
vimentin clone V9, 1:500 (DAKO). 
The scoring of vimentin and E-cadherin was based on 
previously published methods (26, 27). Vimentin staining 
was scored as follows: 0 = no expression, 1 = fragmented 
membranous and/or weak to moderate expression, 
2 = fragmented strong or fully membranous moderate 
expression, and 3 = fully membranous strong expression. 
A score of ≥2 was considered as positive vimentin 
expression. The area intensity score method was used to 
score E-cadherin, which incorporates both the staining 
intensity and the number of positive cells. The intensity of 
staining was scored as 0 = negative, 1 = weak, 2 = moderate, 
and 3 = intense. The percentage of positively stained cells 
was scored as follows; 0 = 0–5% positive cells, 1 = 6–25% 
positive cells, 2= 26–50% positive cells, 3 = 51–75% positive 
cells, and 4 = 75–100% positive cells. The two scores for the 
intensity and the percentage of positive cells were then 
multiplied to generate a final score ranging from 0 to 12. 
E-cadherin expression was dichotomised as negative (score 
of 0–6) and positive (score of 7–12) for outcome analyses. 
Patients considered to be EMT positive were those that were 
scored both vimentin ‘positive’ and E-cadherin ‘negative’. 
PD-L1 expression was scored based on the percentage 
of immunopositively stained cancer cells, with a score 
of ≥1% considered positive PD-L1 staining. Scoring of 
CD8 expression was performed as previously described 
(28). Briefly, a quantitative score based on the percentage 
of immunopositively stained cells among total cells was 
given according to the following scale: 1 (<1% cells); 2 
(1–10% cells); 3 (11–33% cells); 4 (34–66% cells) and 5 
(67–100% cells). Staining intensity was then scored 
as follows: 0 (none), 1+ (mild), 2+ (moderate), and 3+ 
(intense). Finally, Allred scores (ranging from 1 to 8) were 
calculated by adding the percentage positivity scores and 
the intensity scores for each of the sections. The median 
value was used to separate the patient cohort into two 
groups with either negative or positive CD8 expression. 
Figure  1 provides representative cases of E-cadherin, 
vimentin, PD-L1 and CD8 scoring. Two authors 
(T Y and M A) blinded to tumour clinicopathological 
characteristics and patient outcomes scored the slides, 
with any discrepancies resolved by consensus.
Cell culture
The follicular thyroid cancer (FTC) and PTC cell lines 
FTC-133 and K1 were cultured in DMEM: Ham’s F12 (1:1) 
medium (Sigma-Aldrich) containing 2 mM glutamine 
(Thermo Fisher) and 10% foetal bovine serum (FBS) (Thermo 
Fisher). The anaplastic thyroid cancer (ATC) cell line 8505C 
was cultured in EMEM (HBBS) medium supplemented with 
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2 mM glutamine (ThermoFisher), 1% non-essential amino 
acids (Sigma-Aldrich) and 10% FBS (Thermo Fisher). All 
media were supplemented with penicillin-streptomycin 
(Thermo Fisher) and all cells were incubated at 37°C in 5% 
CO2. EMT was induced using recombinant human IFN-γ 
(300-02) (10 ng/mL, Peprotech). 
Live cell imaging assays were performed using the 
IncuCyte® Live-Cell Analysis System (Essen BioScience, Ann 
Arbor, MI, USA). Cells were imaged at 10× magnification at 
37°C with 5% CO2. Images were acquired every 4 h for 48 h. 
Western blot analysis
Western blotting was performed as described previously 
(29). Briefly, cells were harvested and lysed in RIPA buffer 
supplemented with phosphatase (sodium fluoride, sodium 
molybdite, sodium pyrophosphate) and complete Mini, 
EDTA-free protease inhibitors (Roche). 15–25 μg total 
protein (depending on different proteins) were separated 
by SDS-PAGE and then transferred to polyvinylidene 
difluoride membranes (Roche). For each gel, the same 
amount of protein was loaded per lane. Membranes were 
then blocked in 5% non-fat milk in Tris-buffered saline-
Tween for1 h. The immunoblotting was performed by 
incubation at 4°C overnight with the following primary 
antibodies: anti-PD-L1 antibody (13684) (Cell Signaling 
Technology), anti-E-cadherin (ab15148) (Abcam), anti-
vimentin (ab92547) (Abcam) and β-actin (Cell Signaling 
Technology), which was used as an endogenous protein 
for normalisation. Blots were then washed and incubated 
with a 1:1000 dilution of anti-Rabbit IgG H&L (HRP)-
conjugated secondary (Cell Signaling Technology) or a 
1:1000 dilution of anti-mouse IgG H&L (HRP)-conjugated 
secondary (Cell Signaling Technology). Signals were 
detected by enhanced chemiluminescence Plus reagents 
(PerkinElmer) and images were captured using a Licor 
Odyssey System. Signal quantification was obtained using 
Image Studio Lite software (Version 5.2.5). All experiments 
were performed in triplicate. 
Dataset analysis
Normalised gene expression profiles (RNA Seq V2 RSEM) of 
516 PTC patients were retrieved from The Cancer Genome 
Atlas (TCGA) via the Cancer Genomics Data Server 
package (cgdsrv1.2.10; github.com/cBioPortal/cgdsr). The 
EMT score was computed using the mean expression of 
mesenchymal genes (ZEB1, ZEB2, SNAI1, SNAI2, TWIST1, 
TWIST2, VIM, FOXC2, SOX10, FN1, MMP2, MMP3) 
minus the mean expression of epithelial genes (CDH1, 
CLDN3, CLDN4, CLDN7, DSP), as previously described by 
Alsuliman et  al. (22). The IFN gene signature was based 
on the 18-gene tumour inflammation signature reported 
by Ayers et al. (30), which included the following genes; 
PSMB10, HLA-DQA1, HLA-DRB1, CMKLR1, HLA-E, NKG7, 
CD8A, CCL5, CXCL9, CD27, CXCR6, IDO1, STAT1, 
TIGIT, LAG3, CD274, PDCD1LG2, CD276. Correlation 
coefficients of PD-L1 expression and EMT score, or mean 
expression of the IFN signature genes and EMT score were 
computed using Pearson correlation. Survival analyses 
(Kaplan-Meier) based on DFS were performed using 
the survival package (v2.44 1.1; github.com/therneau/
survival). The heatmap was generated using the Complex 
Heatmap package (v2.1.0) (31). All data analyses have 
been performed using R version 3.6.0.
Figure 1
Representative staining of formalin-fixed paraffin-embedded (FFPE) tissues 
from PTC patients. Negative (A) and positive (B) immunohistochemical (IHC) 
staining pattern for E-cadherin expression. Negative (C) and positive (D) IHC 
staining pattern for vimentin expression. Negative (E) and positive (F) IHC 
staining pattern for PD-L1 expression. Negative (G) and positive (H) IHC 
staining pattern for CD8+ expression. Images were taken at 5× 
magnification (A) and 40× magnification (remaining images). 
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Correlations were analysed using the Pearson’s chi-
squared test and Fisher’s exact test. The student t-test 
with Welch’s correction was implemented to compare 
differences between control and treated cell lines. 
Two-sided P values < 0.05 was considered statistically 
significant. Results are representative of three independent 
experiments and are expressed as mean ± s.d. Survival 
curves were plotted using the Kaplan-Meier method and 
compared using the log-rank test. A Cox regression model 
was used to perform multivariate analyses. All statistical 
analyses were completed using GraphPad Prism v.7.0d 
and SPSS software (version 22). 
Results
Patient characteristics
The main characteristics of the 74 PTC patients included 
in the study are detailed in Table 1. The median age of the 
patients at diagnosis was 51 years. The majority of patients 
were female (65/74) or had a tumour size less than 2 cm 
(59/74). Only 10 patients in the cohort were diagnosed 
with TNM stage III/IV disease. This was expected as the 
majority of thyroid cancers are identified and diagnosed 
at an early stage. 
PD-L1 expression is associated with EMT status in 
papillary thyroid cancer patients
The expression of E-cadherin, vimentin, PD-L1 and 
CD8were all assessed via IHC staining of TMAs. Of the 
74 cases, 16 were scored positive for E-cadherin whilst 51 
patients expressed positive vimentin staining. Forty-five 
cases were considered EMT positive (E-cadherin negative 
and vimentin positive). Positive PD-L1 expression was 
observed in 49 patients. PD-L1 positivity was significantly 
higher in PTC patients displaying a mesenchymal 
phenotype (Fig. 2; P = 0.012), as determined by negative 
E-cadherin and positive vimentin expression. Elevated 
CD8 levels were identified in 39 patients. 
PD-L1, EMT and CD8 are predictive for DFS in 
PTC patients
EMT status and the expression of PD-L1, E-cadherin, 
vimentin, and the presence of CD8T cells were not 
significantly associated with any clinicopathological 
characteristics (Supplementary Tables 1, 2, 3, 4 and 5, 
see section on supplementary materials given at the end 
of this article). Interestingly, all six PTC patients which 
experienced lymphovascular invasion were EMT positive 
(i.e. displayed a mesenchymal phenotype); however, this 
did not reach statistical significance (Table 2; P = 0.075), 
likely due to the small number of patients in this 
sub-group. 
At the time of analysis, the median duration of 
follow-up of the 74 cases was 45.5 months (range: 
Table 1 Clinical summary of patients.
Patient characteristics Number of patients (n = 74)
Age




























PD-L1 expression is associated with mesenchymal phenotype. Cases were 
separated in PD-L1 negative (blue) (n = 25) and positive (red) (n = 49) 
subgroups. These were then assessed for epithelial vs mesenchymal 
state. By Fisher’s exact test there was a significant positive association 
between PD-L1 expression and a mesenchymal phenotype.
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2–129 months). A total of 16 cases experienced tumour 
persistence and/or recurrence. Univariate analysis 
revealed that e-cadherin was not a significant predictor of 
DFS in our cohort (Fig. 3A; P = 0.384); however, a positive 
vimentin score was significantly associated with a reduced 
DFS (Fig. 3B; P = 0.003). A high density of tumoural CD8T 
cells was a favourable biomarker predictive of improved 
DFS (Table 2, Fig. 3C; P = 0.028), whilst positive PD-L1 
expression was significantly associated with an increased 
incidence of persistent or recurrent disease (Table 2, Fig. 
3D; P = 0.048. The presence of lymph node metastases 
(Table 2; P = 0.006) and lymphovascular invasion 
(P = 0.004) were also significant predictors of DFS on 
univariate analysis in our cohort. 
Subgroup analysis
Based on EMT marker staining, we categorised all 74 
tissue sections into four subgroups; (i) E-cadherinnegative/
vimentinnegative (n = 13), (ii) E-cadherinnegative/vimentinpositive 
(n = 45), (iii) E-cadherinpositive/vimentinnegative (n = 10), and 
(iv) E-cadherinpositive/vimentinpositive (n =6 ). Patients that 
were E-cadherinnegative/vimentinpositive and E-cadherinpositive/
vimentinpositive experienced the shortest DFS compared to 
the other two subgroups (Fig. 4A; P = 0.026). The patients 
were then allocated one of two major subgroups; (i) an 
EMT positive subgroup (n = 45), including patients with 
a negative E-cadherin and positive vimentin scores, or 
(ii) an EMT negative subgroup (n = 29), which included 
Table 2 Univariate and multivariate analysis of clinicopathologic factors associated with DFS in PTC cases.
Patient characteristics
Univariate analysis Multivariate analysis
P value HR 95% CI P value
Age
 <55 vs
 ≥55 0.736 1.986 0.546–7.226 0.298
Sex
 Male vs
 Female 0.362 1.258 0.281–5.643 0.764
TNM stage
 I vs II vs 
 III vs IV 0.061 1.043 0.488–2.231 0.913
Tumour size
 <2 cm vs 
 ≥2 cm 0.327 0.956 0.253–3.608 0.947
Multifocality
 Present vs 
 Absent 0.128 2.340 0.604–9.063 0.219
Extrathyroidal extension
 Present vs 
 Absent 0.154 1.050 0.260–4.241 0.945
Lymphovascular invasion
 Present vs 
 Absent 0.004* 2.826 0.416–19.188 0.288
Lymph node metastases
 Present vs 
 Absent 0.006* 1.819 0.441–7.515 0.408
Concurrent Hashimoto’s thyroiditis
 Present vs 
 Absent 0.424 0.900 0.242–3.346 0.875
PD-L1
 Negative vs 
 Positive 0.048* 3.053 0.599–15.552 0.179
CD8
 Negative vs 





 E-cadpos/Vimpos 0.026* 3.132 1.102–8.897 0.032*
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all other patients. EMT positive cases had a significantly 
higher incidence of recurrence compared to EMT negative 
patients (P = 0.021). On multivariate analyses, EMT status 
remained as the only significant independent predictor 
for DFS (Table 2; P = 0.032). 
Further sub-analysis was performed to assess the 
relationship between PD-L1, EMT and CD8 expression, 
and prognosis. Patients that were scored both EMT and 
PD-L1 negative (n = 39) had the longest DFS compared 
with all other patients (n = 34) (Fig. 4B; P = 0.003). 
Moreover, PD-L1negative/EMTnegative/CD8positive patients 
(n = 7) experienced no recurrent or persistent disease, 
whilst those considered PD-L1positive/EMTpositive/CD8negative 
(n = 15) experienced the shortest DFS (Fig. 4C; P < 0.0001).
Figure 3
Vimentin, CD8+ and PD-L1 were all predictive for 
DFS in the PTC cohort. Kaplan-Meier curves for 
DFS of PTC patients with positive and negative 
E-cadherin expression (E-cadpos (n = 16) vs E-cadneg 
(n = 58); P = 0.384) (A), vimentin expression 
(Vimentinpos (n = 51) vs Vimentinneg (n = 23); 
P = 0.003) (B), CD8+ density (CD8pos (n = 39) vs. 
CD8neg (n = 35); P = 0.028) (C) and positive or 
negative PD-L1 expression (PD-L1pos (n = 49) vs. 
PD-L1neg (n = 25); P = 0.048) (D). P-values were 
calculated by the log-rank test. 
Figure 4
Patients positive for EMT and PD-L1 expression, 
and negative for CD8+ T-cell expression 
experienced the worst DFS on subgroup analysis. 
Kaplan-Meier curves for DFS of PTC patients with 
positive and negative E-cadherin and Vimentin 
expression (E-cadneg/Vimneg (n = 13) vs  
E-cadpos/Vimneg (n = 10) vs E-cadneg/Vimpos (n = 45) 
vs E-cadpos/Vimpos (n = 6); P = 0.026) (A), positive 
and negative EMT status and PD-L1 expression 
(EMTneg/PD-L1neg (n = 39) vs EMTneg/PD-L1pos and 
EMTpos/PD-L1neg and EMTpos/PD-L1pos (n = 35);  
P = 0.003) (B), and positive and negative EMT 
status, PD-L1 expression and CD8 density  
(EMTpos/PD-L1pos/CD8neg (n = 15) vs  
EMTneg/PD-L1neg/CD8pos (n = 7) vs Other (n = 52);  
P < 0.0001) (C). P values were calculated by the 
log-rank test. 
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Clinical datasets and mRNA expression profiles
In order to expand our IHC findings, the normalised 
gene expression profiles of 516 thyroid cancer patients 
were retrieved from TCGA. The profiles were comprised 
of 399 PTCs, 107 FTCs, 1 patient with PDTC, 1 patient 
with well-differentiated thyroid cancer, and 8 thyroid 
cancers that were not otherwise specified. An EMT score 
of each thyroid cancer sample was calculated using the 
mean expression of mesenchymal genes minus the mean 
expression of epithelial genes (additional detail in the 
‘Materials and methods’ section). This was then correlated 
with PD-L1 gene expression, or the mean expression of 
IFN signature genes (Fig. 5F). We observed a moderate 
positive linear relationship between EMT status and 
PD-L1 expression (Fig. 5A; r = 0.481171) and an IFN gene 
signature (Fig. 5B; r = 0.360384). When considering only 
PTCs (n = 399), the correlation coefficient between EMT 
status and PD-L1 strengthened (Fig. 5C; r = 0.502354). 
Moreover, in the subset of PTCs which experienced disease 
recurrence/progression (n = 40), a strong correlation was 
identified between positive PD-L1 and EMT expression 
(Fig. 5D; r = 0.623002). This was also observed when 
patients of all subtypes which experienced disease 
recurrence/progression (n = 49) were included (Fig. 5E; 
r = 0.656826). These results align with the findings from 
our patient cohort, in which we observed a significant 
association between PD-L1 expression and EMT status. 
In the TCGA PTC patient cohort, a higher EMT and 
mesenchymal genes score were both significantly 
associated with poorer DFS outcomes (P = 0.0027 (Fig. 
5G) and P = 0.0085 (Fig. 5H), respectively). Similarly, the 
EMT status remained the only significant predictor for 
DFS on multivariate analysis in our cohort. Together, 
these findings confirm a significant association between 
PD-L1 and EMT status in PTC. 
Figure 5
Correlation of PD-L1 expression, EMT and an IFN gene signature in thyroid cancer using TCGA gene expression dataset. Gene expression dataset from 
the TCGA thyroid cancer samples (total of 516 patients) showing the correlation between PD-L1 expression with EMT score (r = 0.481171) (A), correlation 
between IFN score and EMT score (r = 0.360384) (B). Correlation between PD-L1 expression and EMT score in PTC patients only (n = 399) (r = 0.502354) 
(C). Correlation between PD-L1 expression and EMT score in PTC patients experiencing disease recurrence/progression (n = 40) (r = 0.623002) (D). 
Correlation between PD-L1 expression and EMT score in all patients experiencing disease recurrence/progression (n = 49) (r = 0.656826) (E). Heat map 
showing mRNA expression level of epithelial genes, mesenchymal genes, and IFN-γ related genes (F). Kaplan-Meier curves for DFS of TCGA thyroid cancer 
patients with positive and negative EMT score (P = 0.0027) (G) and positive and negative mesenchymal gene expression (P = 0.0085) (H). 
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IFN-γ induced PD-L1 expression and EMT in vitro
In order to investigate the relationship between PD-L1 
expression and EMT status, PD-L1 expression was induced 
via IFN-γ treatment in three thyroid cancer cell lines (K1; 
papillary thyroid cancer, FTC-133; follicular thyroid cancer, 
8505C; anaplastic thyroid cancer). Following treatment, 
changes in PD-L1, E-cadherin and vimentin protein 
expression were assessed via Western blot. Treatment 
with 10 ng/mL of IFN-γ for 48 h significantly increased 
the expression of PD-L1 in all cell lines (Fig. 6A, B and C). 
Upregulation in PD-L1 occurred alongside a significant 
decrease in E-cadherin and increase in vimentin expression 
in two of the thyroid cancer cell lines examined (Fig. 6A 
and B). In the 8505C and K1 cell lines, the morphological 
appearance changed from cobblestone tightly arranged 
cells (epithelial like) to spindle -shaped cells that were 
widely distributed (mesenchymal like) (Fig. 6D and E). 
These findings were not observed in the FTC cell line. The 
FTC-133 cell line, which was originally obtained from a 
lymph node metastasis of a patient with FTC, demonstrates 
a spindle-shaped morphology at baseline (Fig. 6F) as well 
as strong levels of vimentin expression in untreated cells 
(Fig. 6C). This cell line may therefore possess a more 
mesenchymal phenotype constitutively and may not be 
expected to undergo the same morphological changes 
observed in 8505C and K1 cells. Collectively, these results 
suggest that IFN-γ treatment promoted PD-L1 expression 
and induced EMT characteristics in K1 and 8505C cells.
Discussion
The significant role of the PD-1/PD-L1 pathway in 
suppressing the anti-tumour immune response has been 
well established (32). PD-1/PD-L1 pathway proteins are 
Figure 6
IFN-γ treatment upregulated PD-L1 expression and induced EMT in thyroid cancer cell lines. PD-L1, E-cadherin and vimentin expression following 48-h  
10 ng/mL IFN-γ treatment in 8505C (A), K1 (B) and FTC-133 (C) thyroid cancer cells lines. A morphological change indicative of EMT was observed in the 8505C 
(D) and K1 (E) cell lines. This was not evident in the FTC (F) cell line which demonstrated a more mesenchymal morphology at baseline. Quantification of 
Western blotting data (n = 3) was performed via Licor Odyssey, which showed a significant reduction in PD-L1 expression in all cell lines assessed. P values 
were calculated by the student t test with Welch’s correction. *P < 0.05, **P < 0.01. All experiments were performed in triplicate. The bars in each column 
show the mean, and the error bars demonstrate the s.d. from three independent experiments. The scatter dot plots represent the individual data points.
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highly expressed in patients with more aggressive thyroid 
cancer variants. Whilst stage I PTCs exhibited low levels 
of cytoplasmic PD-L1 staining assessed via IHC, markedly 
increased expression has been observed in stage III and 
IV PTC cases (33). A significant increase in membrane 
PD-L1 expression was correlated with a higher risk of 
aggressive disease, distant metastasis and death in stage IV 
patients (33). We have recently published a meta-analysis 
confirming that elevated PD-L1 status is a prognostic 
indicator for reduced DFS in patients with non-medullary 
thyroid carcinoma (12). Patients with upregulated PD-L1 
were up to three times as likely to have a poorer prognosis 
than those with negative PD-L1 expression. These 
findings suggest that PD-L1 may provide clinicians with 
a prognostic biomarker capable of identifying thyroid 
cancer patients with aggressive disease at an earlier stage 
and may be useful in the selection of individuals that 
would derive durable clinical benefit from anti-PD-1/
PD-L1 immunotherapy.
Immunotherapies targeting the PD-1/PD-L1 axis 
have exhibited durable responses and improved survival 
rates across numerous cancer types (34). However, a large 
fraction of patients still fail to benefit from treatment, 
with response rates of less than 20% often reported (35). 
The evaluation of PD‐L1 expression via IHC is currently 
the most widely implemented tool used in the selection 
of patients for treatment with PD-1/PD-L1 directed 
immunotherapies (36). Several concerns regarding its 
use have been recognised, including inconsistencies in 
expression between archival versus fresh biopsy, inter- and 
intra-tumoural heterogeneity and a lack of standardisation 
between assays (37). Moreover, response rates of 11 to 
20% have been reported in patients with negative PD-L1 
expression, highlighting its limited use as an independent 
biomarker for immunotherapy response (38). 
The incorporation of additional predictive markers 
may improve patient selection and prevent avoidable 
toxicities and costs in individuals unlikely to benefit 
from treatment. EMT status has recently been identified 
as a potential candidate marker that can be implemented 
alongside PD-L1 to predict patient outcomes and 
response to therapy (39). Positive PD-L1 expression 
was significantly associated with the presence of EMT 
in the tumour tissues from 50 patients diagnosed with 
head and neck squamous cell carcinoma (19). Overall 
survival was significantly reduced in PD-L1 positive 
patients also demonstrating EMT features; these findings 
were confirmed in an independent validation cohort 
and two public databases. Similar findings have been 
observed in non-small-cell lung carcinoma (NSCLC) (40), 
thymic carcinoma (41), extrahepatic cholangiocarcinoma 
(42), oral squamous cell carcinoma (43), oesophageal 
squamous cell carcinoma (OSCC) (44) and hepatocellular 
carcinoma (45). We have also determined that PTC patients 
exhibiting a mesenchymal phenotype were more likely 
to co-express tumoural PD-L1 (P = 0.012). These findings 
were confirmed in the TCGA dataset analysis, in which a 
moderate positive linear relationship between EMT status 
and PD-L1 expression (r = 0.481171) as well as an IFN gene 
signature (r = 0.360384) was observed. In the subset of 
PTCs which experienced disease recurrence/progression 
(n = 40), a stronger correlation was identified between 
positive PD-L1 and EMT expression (r = 0.623002); this 
was further strengthened when patients of all subtypes 
were included in the analysis (n = 49) (r = 0.656826). 
PD-L1, EMT status and CD8T cell expression were all 
not significantly associated with any clinicopathological 
characteristics; this may be a consequence of the relatively 
small cohort size, and the limited number of patients 
presenting with metastatic disease. EMT status remained 
the only significant predictor of DFS on multivariate 
analysis (P = 0.032); these findings were also reflected in 
the TCGA PTC patient cohort, in which a higher EMT 
and mesenchymal genes score were both significantly 
associated with a poorer DFS (P = 0.0027 and P = 0.0085, 
respectively). 
The mechanisms by which EMT regulates components 
of the tumour immune microenvironment, including 
the PD-1/PD-L1 pathway, have recently been elucidated. 
A meta-analysis revealed that PD-L1 gene expression 
was co-amplified along with the EMT associated genes 
MYC, SOX2, N-cadherin and SNAI1 in the endometrial 
and ovarian cancer datasets from TCGA (46). The gene 
promoter region of PD‐L1 contains a binding site for ZEB1, 
a transcription factor which contributes to cancer stemness 
and tumourigenesis (47, 48). siRNA-mediated ZEB1 
knockdown suppressed PD-L1 levels whilst promoting 
E-cadherin expression in OSCC (49). Cases expressing 
high PD‐L1 at the invasive front also had significantly 
greater tumour invasion, EMT, and less CD8 lymphocyte 
infiltration. EMT-converted OSCC cell lines expressing 
high levels of PD-L1 at both protein and mRNA levels were 
capable of inducing T‐cell apoptosis to a greater extent 
when compared to the original epithelial type tumour 
cells (44). In breast cancer cell lines, EMT-mediated PD-L1 
upregulation occurred in parallel with the up- and down-
regulation of the stem-cell-related CD44 and CD24 surface 
markers, respectively; this was also accompanied by a 
morphological change from tightly arranged epithelial-
like cells to widely distributed mesenchymal-like cells 
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(22). A molecular relationship between EMT and CD8 T 
cells was demonstrated by Chen et al., in which ZEB1, an 
EMT activator and transcriptional repressor of miR-200 (a 
cell-autonomous suppressor of EMT and metastasis), was 
shown to relieve miR-200 repression of PD-L1 on tumour 
cells, resulting in CD8 T-cell immunosuppression and 
metastasis. These findings were further supported by a 
strong correlation between EMT score, levels of miR-200 
and PD-L1 expression in numerous human lung cancer 
datasets. Preclinical models of melanoma, pancreatic and 
breast cancer have also demonstrated that the expression 
of certain transcription factors, such as Snail or Neu, can 
induce EMT and are associated with the activation of 
immunosuppressive cytokines and T-cell resistance. In our 
study, the prognostic capabilities of EMT were markedly 
enhanced when used in conjunction with PD-L1 and 
CD8 expression (P < 0.0001). Additional prospective 
studies exploring the interplay between CD8 T cells, EMT/
stromal elements and PD-L1 in larger patient cohorts will 
be needed to confirm these findings. 
PD-1/PD-L1 oncogenic signalling has also been 
shown to play an important role in the regulation of EMT. 
Atezolizumab, an anti‐PD‐L1 checkpoint inhibitor, was 
shown to downregulate genes promoting cell migration, 
invasion and metastasis in the human triple negative 
breast cancer cell line MDA-MB-231 (50). In human 
glioblastoma multiform (GBM) cells, PD-L1 significantly 
altered cell growth, migration and invasion pathways by 
upregulating N-cadherin, vimentin, Slug (an E-cadherin 
transcriptional suppressor) and β-catenin (activates EMT 
via the PI3K/Akt/mTOR pathway), and downregulating 
E-cadherin gene expression (51). PD-L1 overexpression 
promoted GBM development and invasion in orthotopic 
GBM rat models. Following 48 h of IFN-γ treatment, we 
also detected a significant increase in PD-L1 expression in 
all thyroid cancer cell lines examined. This rise in PD-L1 
was accompanied by phenotypic changes indicative of a 
mesenchymal phenotype on imaging. This was confirmed 
on Western blot, where a significant downregulation in 
E-cadherin expression and upregulation of vimentin 
levels was observed. Similar findings were reported by 
Lo et  al., in which IFNs enhanced RCC invasiveness by 
increasing both Slug and ZEB1 gene expression (52). 
IFN-γ induced PD-L1 upregulation may therefore be 
involved in promoting EMT and may prove to be the 
missing link in the treatment of mesenchymal cancers. 
It is important to note that stromal cells have also been 
identified as a key source of EMT-related gene expression 
in colorectal, head and neck, and urothelial cancer (53, 
54, 55). In a cohort of patients with metastatic urothelial 
cancer treated with nivolumab, patients with T-cell 
infiltrated tumours and higher EMT/stroma-related gene 
expression experienced lower response rates and shorter 
progression-free and overall survival (53). Future research 
is required to delineate the distinct roles of PD-L1 and 
tumour-infiltrating stromal cells in activating EMT in 
thyroid cancer. Collectively, these studies illuminate the 
complex bidirectional regulation between EMT and PD-L1 
signalling in cancer which ultimately leads to tumour 
immune escape and invasion.
Interestingly, an integrated analysis of the genomic 
and proteomic profiles from over 1000 tumours revealed 
that additional targetable immune checkpoints are 
present in cancers displaying an EMT phenotype, 
including T-cell immunoglobulin and mucin-domain 
containing-3 (TIM-3), OX40 and cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) (56). EMT may therefore 
accelerate cancer growth and metastasis not only through 
the direct reprogramming of the PD-1/PD-L1 axis, but also 
via the modulation of several immune processes within 
the tumour microenvironment. This finding highlights 
the possibility of utilising EMT status as a supplementary 
tool for the selection of patients who may benefit from 
immune checkpoint inhibitors. Therapies targeting these 
additional immune checkpoints may impede tumour 
metastases and drug resistance mediated via EMT. 
EMT status has also been shown to influence the degree 
of response to PD-1/PD-L1 targeted immunotherapies. 
Mammary tumour cells arising from epithelial carcinoma 
cell lines were found to express lower levels of PD-L1 
and elevated MHC-I, CD8 T cells and M1 (anti-tumour) 
macrophages (57). In contrast, tumours from more-
mesenchymal carcinoma cell lines exhibited low levels of 
MHC-I and an elevated expression EMT markers, PD-L1, 
regulatory T cells, M2 (pro-tumour) macrophages and 
exhausted CD8 T cells within their stroma. The more 
mesenchymal carcinoma cells within a tumour were able to 
safeguard their more epithelial counterparts from immune 
attack, implicating the role of EMT in the regulation of the 
tumour microenvironment. Moreover, epithelial tumours 
were more susceptible to elimination by immunotherapy 
than corresponding mesenchymal tumours. Therefore, 
the implementation of EMT inhibitors as adjuvants to 
immune checkpoint immunotherapies may enhance 
responses in patients with mesenchymal tumours. In 
patients with advanced melanoma, EMT signatures and 
mesenchymal‐related genes were associated with innate 
anti-PD-1 resistance (58). Additionally, patients with 
bladder tumours characterised by an epithelial phenotype 
had significantly higher response rates following 
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treatment with atezolizumab therapy compared to those 
harbouring a basal subtype (59). M7824, a novel first-in-
class bifunctional anti-PD-L1 and TGF-β fusion protein, 
was shown to revert TGF-β mediated mesenchymalisation 
in NSCLC cells, as well as promote the activation of 
CD8 T and NK cells, reduce tumour growth and extend 
survival in animal models of colon and breast cancer. The 
concurrent blockade of the PD-L1 and TGF-β pathways 
elicited superior antitumour activity compared to either 
monotherapy alone. These findings suggest that the 
efficacy of anti-PD-1/PD-L1 checkpoint inhibitors may 
be influenced by an individual’s EMT status. Additional 
trials investigating the efficacy of combination strategies 
comprised of EMT targeted agents and immune checkpoint 
inhibitors will be needed to overcome patient resistance 
and improve survival outcomes.
There were a number of limitations present in our 
study, including its retrospective design, short median 
follow-up, and small sample size. Moreover, it is 
important to note that TMAs may not be representative 
of the whole patient specimen. Prospective, longitudinal 
studies with larger sample sizes will be needed to confirm 
the predictive value of PD-L1, CD8 T-cells and an EMT 
signature in thyroid cancer.
In conclusion, our results reveal the significant 
prognostic capabilities of PD-L1 expression, CD8 T cell 
status and EMT in PTC. Moreover, we provide a feasible 
mechanism for the promotion of EMT in thyroid cells that is 
mediated by PD-L1 expression in vitro. Patients exhibiting 
an EMT phenotype and positive PD-L1 expression may 
benefit from PD-1/PD-L1 targeted immunotherapy. 
Additional research exploring the molecular mechanisms 
underlying EMT regulation and its association with the 
PD-1/PD-L1 axis will enhance our understanding of thyroid 
carcinogenesis and provide alternative approaches for the 
treatment of patients with aggressive disease.
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